ClinicalTrials.gg
Not yet recruitingNCT07951164Updated Nov 20, 2026

The Effect of Acupuncture on Brain-Derived Exosomal Load, Cognitive Function, and Sleep Disturbances in Patients With Fibromyalgia.

An observational study in Fibromyalgia, sponsored by University of Crete. Not yet recruiting at 1 site in Greece. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Crete · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this observational study is to learn about the effects of electroacupuncture on exosome load and clinical outcomes in patients with fibromyalgia, a chronic condition characterized by widespread pain, fatigue, sleep disturbances, and cognitive dysfunction.

The main questions it aims to answer are:

  1. Does acupuncture alter the load of circulating exosomes in patients with fibromyalgia?
  2. Is a change in exosome load associated with improvements in pain, cognitive function, and sleep quality?
  3. Can exosome load serve as a potential biomarker of brain-related changes in conditions involving chronic pain?

Participants with fibromyalgia receiving electroacupuncture as part of their routine clinical care will provide blood samples before and after treatment for exosome analysis. Participants will also undergo assessments of mechanical pain threshold, pain intensity, overall symptom burden, cognitive function (using objective neuropsychological tests and self-report questionnaires), and sleep quality. Healthy volunteers will be included as a comparison group.

Read the detailed description

Chronic pain has emerged as a major public health challenge, affecting millions of individuals worldwide and imposing a substantial socioeconomic burden. Beyond physical suffering, chronic pain is increasingly recognized as a condition associated with cognitive impairment, including deficits in memory, attention, executive function, and information processing.

According to the neural resource theory, persistent pain continuously consumes cognitive resources, thereby reducing the brain's ability to perform higher cognitive tasks. However, several additional mechanisms have been proposed, including neuroplastic alterations, neuroinflammation mediated by microglial activation, psychosocial factors, and disturbances of the gut-brain axis.

Recent advances in extracellular vesicle biology have highlighted the importance of exosomes as mediators of intercellular communication. Brain-derived exosomes are capable of crossing the blood-brain barrier and carry proteins, lipids, messenger RNAs, microRNAs, and other molecular cargo reflecting ongoing pathological processes within the central nervous system. Emerging evidence suggests altered exosomal microRNA profiles in fibromyalgia patients, while other studies have demonstrated associations between exosome-related biomarkers and neurodegenerative processes, cognitive decline, and sleep disorders. Nevertheless, review of the literature suggests that no study has comprehensively investigated the relationship between exosomal alterations, cognitive dysfunction, sleep disturbances, and response to electroacupuncture in fibromyalgia.

Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive dysfunction. Cognitive symptoms, often described as "fibro fog," significantly impair daily functioning and quality of life. Despite increasing recognition of these manifestations, the biological mechanisms linking chronic pain to cognitive impairment remain poorly understood. Fibromyalgia represents an ideal clinical model for investigating these interactions because it combines chronic widespread pain with pronounced cognitive dysfunction and sleep disturbances. Previous studies have demonstrated alterations in functional brain networks, inflammatory pathways, and neuroendocrine regulation in patients with fibromyalgia.

The overall objective of this study is to investigate whether brain-derived exosomes can serve as biomarkers of pain-related cognitive dysfunction and sleep disturbances in patients with fibromyalgia and whether their profile is modified following pain treatment.

The specific objectives are:

  1. To compare brain-derived exosomal load between patients with fibromyalgia and healthy controls.
  2. To evaluate the effects of electroacupuncture on exosomal load and composition.
  3. To assess the relationship between exosomal load and clinical outcomes, including pain severity, symptom burden, cognitive performance, and sleep quality.
  4. To explore whether changes in exosomal load correlate with treatment-induced clinical improvement.
02

Conditions studied

  • Fibromyalgia

Keywords

  • Fibromyalgia
  • Electroacupuncture
  • Chronic widespread pain
  • Quality of life
  • Mechanical threshold of pain
  • Exosomal load
  • Cognitive dysfunction
03

In context

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 255 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 279 observational studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

University of Crete is the lead sponsor of 25 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants that are included in the Fibromyalgia Cohort, are patients with widespread musculoskeletal pain, who are referred to Chronic Pain Clinic of University hospital of Heraklion from Rheumatologists, after excluding other rheumatologist diseases and confirming the diagnosis of Fibromyalgia. They will be enrolled in the study if only they meet inclusion criteria and they do not meet exclusion criteria Participants in the Healthy Cohort, are healthy volunteers, that meet inclusion criteria of the study.

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria for the Healthy Cohort

Participants will be eligible for inclusion in the Healthy Cohort group if they meet all of the following criteria:

  1. Age between 18 and 70 years.
  2. Absence of any chronic pain condition or other medical disorder known to affect systemic inflammatory burden during the study period.
  3. Absence of cognitive impairment, as assessed by the (MoCA) and the Trail Making Test (TMT) Parts A and B. The criterion for the absence of cognitive impairment, as assessed by the Montreal Cognitive Assessment (MoCA), is a score of 26 or higher (≥26), as recommended in the literature.
  4. Absence of poor sleep quality, defined according to the Pittsburgh Sleep Quality Index (PSQI).
  5. No history of depression or other neuropsychiatric disorders. If healthy volunteers are found to have depression or any other neuropsychiatric disorder, they will be immediately referred for psychiatric and psychological assessment.
  6. No use of antidepressant medications or sleep-promoting agents, including herbal or over-the-counter sleep aids.

Inclusion Criteria for the Fibromyalgia Cohort

Participants will be eligible for inclusion in the fibromyalgia group if they meet all of the follow-ing criteria:

  1. Diagnosis of fibromyalgia established by a rheumatologist according to the American College of Rheumatology (ACR) 2010 classification criteria.
  2. Age between 18 and 70 years.
  3. Moderate-to-severe pain intensity, defined as a Visual Analogue Scale (VAS) score ≥ 4/10.
  4. Presence of cognitive difficulties documented through the Montreal Cognitive Assess-ment (MoCA) and the Trail Making Test (TMT) Parts A and B. The criterion for the presence of cognitive impairment, as assessed by the Montreal Cognitive Assessment (MoCA), is a score below 26.
  5. Poor sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score ≥ 5.

Exclusion Criteria:

Exclusion Criteria for the Fibromyalgia Group

Participants meeting any of the following criteria will be excluded from the study:

  1. Coexisting neurological disorders associated with cognitive impairment, including dementia.
  2. Coexisting psychiatric disorders known to affect cognitive function, including major depressive disorder, bipolar disorder, or schizophrenia. Major depression will be defined as a Patient Health Questionnaire-9 (PHQ-9) score ≥ 20.
  3. Presence of medical conditions associated with altered inflammatory burden, including rheumatologic diseases.
  4. Use of sleep medications that cannot be safely discontinued prior to study participation.
  5. Antidepressant treatment that cannot either be discontinued or maintained at a stable dosage for at least three months before treatment initiation and throughout the entire study period.

5. Severe cognitive impairment resulting in an inability to understand the Participant Information Sheet and provide , as assessed by the Montreal Cognitive Assessment (MoCA). Patients with a score below 18/30 will be excluded from the study and referred to the appropriate healthcare professional for further assessment and management.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Fibromyalgia cohort

    Patients diagnosed with Fibromyalgia

    Procedure: Electroacupuncture

  • Healthy cohort

    Healthy volunteers, age, sex and education level matched to Fibromyalgia cohort

Interventions

  • ProcedureElectroacupuncture

    \*\*Electroacupuncture Intervention\*\* Participants in this group will receive electroacupuncture treatment for 24 weeks. During the first 6 weeks, treatment sessions will be administered twice weekly. Thereafter, participants will receive maintenance treatments every two weeks until completion of the 24-week intervention period. A standardized electroacupuncture protocol will be applied using the following acupuncture points: * GV20 (Baihui) * EX-HN3 (Yintang) * BL10 (Tianzhu) * GB21 (Jianjing) * BL60 (Kunlun) * ST36 (Zusanli) * LV3 (Taichong) * SP6 (Sanyinjiao) * LI4 (Hegu) * LI11 (Quchi) * KI3 (Taixi) * CV6 (Qihai) * CV12 (Zhongwan) * HT7 (Shenmen) Additional individualized points will be used if required. Sterile, single-use disposable needles will be inserted at the specified acupoints. Electrical stimulation will be applied according to the study protocol.

06

What researchers measure

Primary outcomes

  1. Brain-derived exosomes - Changes in exosomal load

    Changes in exosomal cargo, exosomal protein expression and molecular signatures relevant to neuroinflammation, neuronal dysfunction, and neurodegeneration will be analyzed by comprehensive proteomic profiling of exosomes (label-free, non-targeted proteomics). This outcome will be assessed in both Cohorts of the study.

    Time frame: In the Fibromyalgia Cohort this outcome will be assessed before treatment, at 6 weeks, and at 6 months after treatment initiation. In the Healthy Cohort this outcome will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.

Secondary outcomes

  1. Objective Cognitive Assessment - Greek version of the Trail Making Test (TMT) Part A

    Objective changes in cognitive function from treatment will be assessed using the Greek version of the Trail Making Test (TMT) Part A. Raw scores will be converted to age-, sex-, and education-adjusted z-scores using Greek normative data to facilitate comparisons between groups. This outcome will be assessed in both groups.

    Time frame: For participants belonging to the Fibromyalgia Cohort, scores will be assessed Before treatment (baseline), at 6 weeks, and at 6 months. In the Healthy Cohort, scores will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.

  2. Objective Cognitive Assessment - Greek version of the Trail Making Test (TMT) Part B

    Objective changes in cognitive function from treatment will be assessed using the Greek version of the Trail Making Test (TMT) Part B. Raw scores will be converted to age-, sex-, and education-adjusted z-scores using Greek normative data to facilitate comparisons between groups. This outcome will be assessed in both groups.

    Time frame: For participants in the Fibromyalgia Cohort, scores will be assessed Before treatment (baseline), at 6 weeks, and at 6 months. In the Healthy Cohort, scores will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.

  3. Pain Assessment - BPI Short Form questionnaire - Change of Pain Interference score

    Pain's impact on participants' daily functioning will be assessed using the Brief Pain Inventory (BPI) Short form questionnaire. The Pain Interference score will be calculated by adding the scores from Items 9A-9G and divided by 7. This outcome will be assessed only in Fibromyalgia Cohort.

    Time frame: Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

  4. Pain Assessment - BPI Short Form questionnaire - Change of Pain severity score

    Pain intensity will be assessed using the Brief Pain Inventory (BPI) Short Form questionnaire. The Pain severity score will be calculated by adding the scores from Items 3-6 and divided by 4. This outcome will be assessed only in Fibromyalgia Cohort.

    Time frame: Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

  5. Pain Assessment - BPI Short Form questionnaire - Change of percentage relief from treatment

    Pain relief from treatment will be assessed using the Brief Pain Inventory (BPI) Short Form questionnaire. The Pain relief from treatment will be assessed by Items 8 of questionnaire. This outcome will be assessed only in Fibromyalgia Cohort.

    Time frame: Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

  6. Pain Assessment - Algometer - Change of Mechanical threshold of Pain

    Mechanical threshold of participants' pain in Fibromyalgia Cohort will be assessed using the Algometer. By the algometer pressure will be applied to two-four painful points and the patients will indicate by pressing a button the pressure that provokes pain. This outcome will be assessed only in Fibromyalgia Cohort.

    Time frame: Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

  7. Objective Cognitive Assessment - Greek version of Montreal Cognitive Assessment Test (MoCA)

    Objective changes in cognitive function from treatment will be assessed using the Greek Version of Montreal Cognitive Assessment Test (MoCA) . Scores will result from summing the scores from the individual tests of MOCA as indicated from the authors. This outcome will be assessed in both groups.

    Time frame: For participants in the Fibromyalgia Cohort, scores will be assessed before treatment (baseline), at 6 weeks, and at 6 months. Scores in the Healthy Cohort will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment in study.

  8. Sleep Disturbances - Pittsburgh Sleep Quality Index (PSQI)

    Sleep quality changes will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated instrument for the evaluation of subjective sleep quality and sleep-related disturbances. It groups 19 self-rated questions into 7 component scores, each graded on a scale of 0 to 3. The global score ranges from 0 to 21 and a global score greater than 5 indicates poor sleep quality.

    Time frame: The scores will be assessed in both cohorts before enrollment in the study, at 6 weeks and 6 months after enrollment.

  9. Subjective Cognitive Assessment - Revised Fibromyalgia Impact Questionnaire (FIQ-R) - Changes in cognitive function

    Changes in cognitive function will be assessed using the cognitive subscale of the Revised Fibromyalgia Impact Questionnaire (FIQ-R), which evaluates patients' self-perceived cognitive difficulties. In this sub scale the patient is asked to rate the severity of specific cognitive issues over the past 7 days on a 0-10 numeric scale. This outcome will be assessed only in Fibromyalgia Cohort.

    Time frame: Scores will be assessed only in the Fibromyalgia Cohort before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation, because participants in Healthy Cohort do not experience pain.

07

Study locations

1 site
  • Medical School, University of Crete
    Heraklion, Crete 71110, Greece
08

References and documents

Publications

  • Cherry BJ, Weiss J, Barakat BK, Rutledge DN, Jones CJ. Physical performance as a predictor of attention and processing speed in fibromyalgia. Arch Phys Med Rehabil. 2009 Dec;90(12):2066-73. doi: 10.1016/j.apmr.2009.07.011. PubMed 19969170 ↗
  • Chen X, Chen S, Chen L, Zheng H, Nie J, Yang L, Li X, Ju K. Profiling characteristics of plasma exosomal miRNAs across cognitive stages: from normalcy to mild cognitive impairment and Alzheimer's disease. RSC Adv. 2025 Jul 8;15(29):23670-23680. doi: 10.1039/d5ra02993g. eCollection 2025 Jul 4. PubMed 40630682 ↗
  • Kleinman L, Mannix S, Arnold LM, Burbridge C, Howard K, McQuarrie K, Pitman V, Resnick M, Roth T, Symonds T. Assessment of sleep in patients with fibromyalgia: qualitative development of the fibromyalgia sleep diary. Health Qual Life Outcomes. 2014 Jul 14;12:111. doi: 10.1186/s12955-014-0111-6. PubMed 25017455 ↗
  • Bonomi S, Oltra E, Alberio T. In Search of Molecular Correlates of Fibromyalgia: The Quest for Objective Diagnosis and Effective Treatments. Int J Mol Sci. 2025 Oct 7;26(19):9762. doi: 10.3390/ijms26199762. PubMed 41097025 ↗
  • Sanchez Romero EA, Melendez Oliva E, Alonso Perez JL, Martin Perez S, Turroni S, Marchese L, Villafane JH. Relationship between the Gut Microbiome and Osteoarthritis Pain: Review of the Literature. Nutrients. 2021 Feb 24;13(3):716. doi: 10.3390/nu13030716. PubMed 33668236 ↗
  • Freidin MB, Stalteri MA, Wells PM, Lachance G, Baleanu AF, Bowyer RCE, Kurilshikov A, Zhernakova A, Steves CJ, Williams FMK. An association between chronic widespread pain and the gut microbiome. Rheumatology (Oxford). 2021 Aug 2;60(8):3727-3737. doi: 10.1093/rheumatology/keaa847. PubMed 33331911 ↗
  • Minerbi A, Gonzalez E, Brereton NJB, Anjarkouchian A, Dewar K, Fitzcharles MA, Chevalier S, Shir Y. Altered microbiome composition in individuals with fibromyalgia. Pain. 2019 Nov;160(11):2589-2602. doi: 10.1097/j.pain.0000000000001640. PubMed 31219947 ↗
  • Shoskes DA, Wang H, Polackwich AS, Tucky B, Altemus J, Eng C. Analysis of Gut Microbiome Reveals Significant Differences between Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Controls. J Urol. 2016 Aug;196(2):435-41. doi: 10.1016/j.juro.2016.02.2959. Epub 2016 Feb 27. PubMed 26930255 ↗
  • Meints SM, Edwards RR. Evaluating psychosocial contributions to chronic pain outcomes. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Dec 20;87(Pt B):168-182. doi: 10.1016/j.pnpbp.2018.01.017. Epub 2018 Jan 31. PubMed 29408484 ↗
  • Loggia ML, Chonde DB, Akeju O, Arabasz G, Catana C, Edwards RR, Hill E, Hsu S, Izquierdo-Garcia D, Ji RR, Riley M, Wasan AD, Zurcher NR, Albrecht DS, Vangel MG, Rosen BR, Napadow V, Hooker JM. Evidence for brain glial activation in chronic pain patients. Brain. 2015 Mar;138(Pt 3):604-15. doi: 10.1093/brain/awu377. Epub 2015 Jan 12. PubMed 25582579 ↗
  • Peterson BS, Potenza MN, Wang Z, Zhu H, Martin A, Marsh R, Plessen KJ, Yu S. An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am J Psychiatry. 2009 Nov;166(11):1286-94. doi: 10.1176/appi.ajp.2009.08050724. Epub 2009 Sep 15. PubMed 19755575 ↗
  • Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005 Aug 24;25(34):7709-17. doi: 10.1523/JNEUROSCI.2177-05.2005. PubMed 16120771 ↗
  • Gonzalez-Roldan AM, Delgado-Bitata M, Dorado A, Costa da Silva I, Montoya P. Chronic pain and its association with cognitive decline and brain function abnormalities in older adults: Insights from EEG and neuropsychological assessment. Neurobiol Aging. 2025 Jun;150:172-181. doi: 10.1016/j.neurobiolaging.2025.03.009. Epub 2025 Mar 18. PubMed 40147351 ↗
  • Jacobsen HB, Brun A, Stubhaug A, Reme SE. Stress specifically deteriorates working memory in peripheral neuropathic pain and fibromyalgia. Brain Commun. 2023 Jul 5;5(4):fcad194. doi: 10.1093/braincomms/fcad194. eCollection 2023. PubMed 37465756 ↗
  • Scherder R, Kant N, Wolf E, Pijnenburg ACM, Scherder E. Pain and Cognition in Multiple Sclerosis. Pain Med. 2017 Oct 1;18(10):1987-1998. doi: 10.1093/pm/pnw290. PubMed 28340237 ↗
  • Croosu SS, Gjela M, Roikjer J, Hansen TM, Morch CD, Frokjaer JB, Ejskjaer N. Cognitive function in individuals with and without painful and painless diabetic polyneuropathy-A cross-sectional study in type 1 diabetes. Endocrinol Diabetes Metab. 2023 Jul;6(4):e420. doi: 10.1002/edm2.420. Epub 2023 Apr 18. PubMed 37073434 ↗
  • Karimi Z, Pilenko A, Held SM, Hasenbring MI. Recall Bias in Patients with Chronic Low Back Pain: Individual Pain Response Patterns Are More Important Than Pain Itself! Int J Behav Med. 2016 Feb;23(1):12-20. doi: 10.1007/s12529-015-9499-6. PubMed 26154771 ↗
  • Tome-Pires C, Miro J. Electrodermal responses and memory recall in migraineurs and headache-free controls. Eur J Pain. 2014 Oct;18(9):1298-306. doi: 10.1002/j.1532-2149.2014.490.x. Epub 2014 Mar 25. PubMed 24664629 ↗
  • Attridge N, Noonan D, Eccleston C, Keogh E. The disruptive effects of pain on n-back task performance in a large general population sample. Pain. 2015 Oct;156(10):1885-1891. doi: 10.1097/j.pain.0000000000000245. PubMed 26020226 ↗
  • Khera T, Rangasamy V. Cognition and Pain: A Review. Front Psychol. 2021 May 21;12:673962. doi: 10.3389/fpsyg.2021.673962. eCollection 2021. PubMed 34093370 ↗
  • Duenas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res. 2016 Jun 28;9:457-67. doi: 10.2147/JPR.S105892. eCollection 2016. PubMed 27418853 ↗
  • Thi Nguy BH, Liu WT, Chang YT, Lin CP, Kang JH. Elevated tau and beta-amyloid in the serum of fibromyalgia patients. CNS Spectr. 2022 Jun;27(3):339-346. doi: 10.1017/S1092852920002114. Epub 2020 Dec 7. PubMed 33280616 ↗
  • Chen Z, Shang Y, Ou Y, Shen C, Cao Y, Hu H, Yang R, Liu T, Liu Q, Song M, Zong D, Xiang X, Peng Y, Ouyang R. Obstructive Sleep Apnea Plasma-Derived Exosomes Mediate Cognitive Impairment Through Hippocampal Neuronal Cell Pyroptosis. Am J Geriatr Psychiatry. 2024 Aug;32(8):922-939. doi: 10.1016/j.jagp.2024.01.017. Epub 2024 Jan 17. PubMed 38290937 ↗
  • Erbacher C, Vaknine-Treidel S, Madrer N, Weinbender S, Evdokimov D, Unterecker S, Moshitzky G, Sommer C, Greenberg DS, Soreq H, Uceyler N. Altered blood and keratinocyte microRNA/transfer RNA fragment profiles related to fibromyalgia syndrome and its severity. Pain. 2024 Dec 6;166(7):1641-1652. doi: 10.1097/j.pain.0000000000003499. PubMed 39679614 ↗
  • Perrot S. Fibromyalgia: A misconnection in a multiconnected world? Eur J Pain. 2019 May;23(5):866-873. doi: 10.1002/ejp.1367. Epub 2019 Feb 11. PubMed 30663833 ↗
  • Moriarty O, Ruane N, O'Gorman D, Maharaj CH, Mitchell C, Sarma KM, Finn DP, McGuire BE. Cognitive Impairment in Patients with Chronic Neuropathic or Radicular Pain: An Interaction of Pain and Age. Front Behav Neurosci. 2017 Jun 13;11:100. doi: 10.3389/fnbeh.2017.00100. eCollection 2017. PubMed 28659771 ↗
  • Canaipa R, Khallouf A, Magalhaes AR, Teodoro R, Pao-Mole V, Agostinho M, Pimentel-Santos F, Honigman L, Treister R. Relations between short-term memory and the within-subject variability of experimental pain intensity reports: Results from healthy and Fibromyalgia patients. PLoS One. 2022 Nov 16;17(11):e0277402. doi: 10.1371/journal.pone.0277402. eCollection 2022. PubMed 36383606 ↗
  • Moore DJ, Eccleston C, Keogh E. Cognitive load selectively influences the interruptive effect of pain on attention. Pain. 2017 Oct;158(10):2035-2041. doi: 10.1097/j.pain.0000000000001011. PubMed 28708762 ↗
  • Segura-Jimenez V, Estevez-Lopez F, Soriano-Maldonado A, Alvarez-Gallardo IC, Delgado-Fernandez M, Ruiz JR, Aparicio VA. Gender Differences in Symptoms, Health-Related Quality of Life, Sleep Quality, Mental Health, Cognitive Performance, Pain-Cognition, and Positive Health in Spanish Fibromyalgia Individuals: The Al-Andalus Project. Pain Res Manag. 2016;2016:5135176. doi: 10.1155/2016/5135176. Epub 2016 Oct 27. PubMed 27867309 ↗
  • Cherup NP, Robayo LE, Vastano R, Fleming L, Levin BE, Widerstrom-Noga E. Neuropsychological Function in Traumatic Brain Injury and the Influence of Chronic Pain. Percept Mot Skills. 2023 Aug;130(4):1495-1523. doi: 10.1177/00315125231174082. Epub 2023 May 23. PubMed 37219529 ↗
  • Zhao L, Zhang L, Tang Y, Tu Y. Cognitive impairments in chronic pain: a brain aging framework. Trends Cogn Sci. 2025 Jun;29(6):570-585. doi: 10.1016/j.tics.2024.12.004. Epub 2025 Jan 2. PubMed 39753445 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 81 non-industry observational studies under Fibromyalgia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 109. This study's planned 24 months is close to that.

Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 8 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951164
Lead sponsor
University of Crete
Responsible party
Vardakis Panagiotis (PhD candidate, University of Crete) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion